Your browser is no longer supported. Please, upgrade your browser.
Settings
VSAR Versartis, Inc. daily Stock Chart
VSAR [NASD]
Versartis, Inc.
Index- P/E- EPS (ttm)-3.18 Insider Own0.90% Shs Outstand34.91M Perf Week-2.27%
Market Cap525.40M Forward P/E- EPS next Y-2.69 Insider Trans211.06% Shs Float34.58M Perf Month1.01%
Income-93.80M PEG- EPS next Q-0.62 Inst Own90.70% Short Float2.09% Perf Quarter27.54%
Sales- P/S- EPS this Y35.40% Inst Trans-0.29% Short Ratio5.46 Perf Half Y34.14%
Book/sh3.75 P/B4.01 EPS next Y12.70% ROA-56.90% Target Price25.71 Perf Year6.97%
Cash/sh4.59 P/C3.28 EPS next 5Y- ROE-64.90% 52W Range6.17 - 16.55 Perf YTD1.01%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-10.57% Beta-
Dividend %- Quick Ratio3.00 Sales past 5Y- Gross Margin- 52W Low139.87% ATR0.84
Employees53 Current Ratio3.00 Sales Q/Q- Oper. Margin- RSI (14)48.38 Volatility4.50% 5.49%
OptionableYes Debt/Eq0.00 EPS Q/Q-33.10% Profit Margin- Rel Volume0.24 Prev Close15.05
ShortableYes LT Debt/Eq0.00 EarningsFeb 02 AMC Payout- Avg Volume132.03K Price14.80
Recom1.90 SMA20-3.93% SMA506.19% SMA20026.48% Volume10,617 Change-1.66%
Dec-20-16Upgrade Credit Suisse Neutral → Outperform
Dec-02-16Initiated SunTrust Buy $25
Oct-04-16Initiated Piper Jaffray Overweight
Dec-17-15Downgrade Credit Suisse Neutral → Underperform
Aug-20-15Initiated Credit Suisse Neutral
Aug-13-15Initiated Morgan Stanley Equal-Weight $17
Jul-07-15Reiterated Canaccord Genuity Buy $20 → $28
Apr-14-15Initiated Sun Trust Rbsn Humphrey Buy $50
Apr-15-14Initiated Canaccord Genuity Buy $36
Jan-13-17 11:00AM  Versartis' Pipeline Holds Big Promise
Jan-09-17 08:40AM  Adamas Pharmaceuticals (ADMS) in Focus: Stock Up 5.4%
Jan-08-17 10:10AM  Huge Energy Trade Kicks Off 2017 Insider Buying: DCP Midstream, Och-Ziff Capital, TransEnterix, Amicus Therapeutics and More
Jan-05-17 08:20AM  Versartis (VSAR) Shares March Higher, Can It Continue?
Jan-04-17 02:47PM  5 Stocks Insiders Are Loading Up On +7.38%
Dec-28-16 04:32PM  VERSARTIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Dec-20-16 07:12AM  Versartis upgraded by Credit Suisse +5.70%
Dec-04-16 03:56PM  150% Surge in Smart Money Ownership of Versartis Inc (VSAR): What Have They Discovered? at Insider Monkey
Nov-29-16 12:41PM  VERSARTIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Nov-28-16 02:23PM  Versartis, Inc. :VSAR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 -5.97%
Nov-10-16 01:04PM  VERSARTIS, INC. Financials
Nov-07-16 07:30AM  Versartis Presents Safety, Efficacy and IGF-I Data for Somavaratan in Pediatric Growth Hormone Deficiency at the 2016 Congress of the GRS & IGF Society GlobeNewswire +6.04%
Nov-04-16 05:19PM  VERSARTIS, INC. Files SEC form 10-Q, Quarterly Report
Nov-03-16 06:48PM  Versartis reports 3Q loss -5.56%
04:12PM  VERSARTIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Versartis Reports Third Quarter 2016 Financial Results GlobeNewswire
Oct-31-16 08:30AM  Versartis to Present at Two Investor Conferences in November GlobeNewswire -9.80%
Oct-17-16 09:00AM  Phase 3 Enrollment Initiated in Japan for Versartis' Long-Acting Growth Hormone Based on Amunix's XTEN(R) Technology Marketwired
Oct-14-16 04:20PM  VERSARTIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Sep-29-16 06:04AM  VERSARTIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Sep-28-16 03:04PM  Ferrellgas Partners LP (FGP), Real Goods Solar Inc (RGSE) Among Stocks on the Move on Wednesday at Insider Monkey -8.25%
09:02AM  Versartis Announces Pricing of Follow-On Offering GlobeNewswire
Sep-27-16 04:01PM  Versartis Announces Proposed Offering of Common Stock GlobeNewswire
Sep-26-16 07:06AM  VERSARTIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  Versartis Initiates Phase 3 Trial of Somavaratan in Japan for Children with Growth Hormone Deficiency Following Completion of Phase 2 GlobeNewswire
Sep-15-16 08:04AM  VERSARTIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Sep-13-16 03:29PM  Versartis, Inc. :VSAR-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016 -6.84%
Sep-12-16 09:11AM  VERSARTIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM  Versartis Presents Data From Up to 30 Months of Somavaratan Treatment for Pediatric Growth Hormone Deficiency at the 2016 ESPE Annual Meeting GlobeNewswire
Sep-06-16 08:35AM  Versartis to Present at the Morgan Stanley Global Healthcare Conference GlobeNewswire
08:30AM  Versartis to Host Investor Symposium Featuring Leading Experts in Growth Hormone Deficiency GlobeNewswire
Sep-02-16 04:18PM  VERSARTIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits -5.10%
04:05PM  Versartis Presents Efficacy, Safety, Metabolic and Adherence Data for Somavaratan in Oral Session at the International Congress of Endocrinology GlobeNewswire
Sep-01-16 03:00AM  Long Acting Growth Hormone Based on Amunix' XTEN(R) Technology Completes Enrollment of Phase 3 Trial Marketwired +6.05%
Aug-22-16 08:30AM  Versartis Announces Completion of Enrollment in Phase 3 VELOCITY Trial of Somavaratan in Pediatric GHD GlobeNewswire
Aug-09-16 04:08PM  VERSARTIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
04:05PM  Teijin Limited and Versartis Enter Strategic Alliance for Commercialization of Somavaratan Long-Acting Growth Hormone in Japan GlobeNewswire
Aug-04-16 08:30AM  Versartis to Present at the Canaccord Genuity 36th Annual Growth Conference GlobeNewswire
Aug-03-16 06:08AM  VERSARTIS, INC. Files SEC form 10-Q, Quarterly Report
Jul-28-16 05:59PM  Versartis reports 2Q loss
04:17PM  VERSARTIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Versartis Reports Second Quarter 2016 Financial Results GlobeNewswire
Jun-29-16 11:06AM  These 15 Biotech Companies Could Be Takeover Targets at Barrons.com +7.27%
Jun-03-16 06:09AM  VERSARTIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Jun-02-16 01:03PM  Versartis, Inc. :VSAR-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 +7.86%
May-23-16 04:03PM  VERSARTIS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders +8.38%
May-04-16 06:14AM  VERSARTIS, INC. Files SEC form 10-Q, Quarterly Report -13.03%
Apr-29-16 06:22AM  VERSARTIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -6.89%
Apr-28-16 06:29PM  Versartis reports 1Q loss
04:05PM  Versartis Reports First Quarter 2016 Financial Results GlobeNewswire
Apr-04-16 09:51AM  Versartis (VSAR) Shares March Higher, Can It Continue?
08:36AM  VERSARTIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM  Versartis Presents Confirmatory Year Two Data from Ongoing Somavaratan Extension Study at Late-Breaker Session at ENDO Annual Meeting GlobeNewswire
Apr-01-16 07:06AM  VERSARTIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
07:00AM  Versartis Presents Confirmatory 18-Month Adherence Data from Ongoing Somavaratan Extension Study at Late-Breaker Session at ENDO Annual Meeting GlobeNewswire
Mar-30-16 08:30AM  Versartis Appoints Colin Hislop, M.D., as Chief Medical Officer GlobeNewswire
Mar-14-16 01:40PM  Versartis Announces Two Abstracts from Ongoing Pediatric Extension Study of Somavaratan Selected for Late-Breaker Presentations at the Endocrine Societys 98th Annual Meeting GlobeNewswire
Mar-08-16 06:07AM  VERSARTIS, INC. Files SEC form 10-K, Annual Report -12.80%
04:00AM  Capella Bioscience Completes Series A Financing of £11 million ($15.5 million) to Progress Antibody Pipeline PR Newswire
Mar-01-16 04:05PM  Versartis to Present at the Cowen and Company 36th Annual Health Care Conference GlobeNewswire +10.35%
Feb-18-16 05:39PM  Versartis reports 4Q loss -5.21%
04:11PM  VERSARTIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Versartis Reports Fourth Quarter and Full Year 2015 Financial Results GlobeNewswire
Feb-03-16 06:07AM  VERSARTIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -5.84%
Feb-02-16 07:06AM  VERSARTIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -11.33%
07:00AM  Versartis Reports Confirmatory Top-Line Two-Year Data from Ongoing Extension Study of Somavaratan in GHD Children GlobeNewswire
01:00AM  Medicxi Ventures, Formerly Index Ventures Life Sciences, Launches as an Independent Venture Capital Firm and Announces Closing of a 210m Fund including GSK and Johnson & Johnson Innovation PR Newswire
Jan-28-16 04:35PM  Versartis to Host Conference Call to Review Two-Year Top-Line Data From Ongoing Extension Study of Somavaratan at noodls -5.40%
04:05PM  Versartis to Host Conference Call to Review Two-Year Top-Line Data From Ongoing Extension Study of Somavaratan GlobeNewswire
Jan-20-16 08:25AM  Versartis (VSAR) Looks Good: Stock Adds 13.2% in Session +9.83%
Dec-16-15 01:38PM  Versartis VRS-317 6-Month Data Published in The Journal of Clinical Endocrinology & Metabolism GlobeNewswire
08:26AM  Direction of Market Influences - Analyst Notes on Maxwell Technologies, Organovo Holdings, Abraxas Petroleum and Versartis Accesswire
Nov-25-15 06:05AM  Versartic Inc (VSAR): Are Hedge Funds Right About This Stock? at Insider Monkey +5.67%
Nov-04-15 06:02PM  VERSARTIS, INC. Files SEC form 10-Q, Quarterly Report
Nov-03-15 04:15PM  Versartis to Present at the Credit Suisse 24th Annual Healthcare Conference GlobeNewswire
Oct-29-15 06:31PM  Versartis reports 3Q loss
04:24PM  VERSARTIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Versartis Reports Third Quarter 2015 Financial Results GlobeNewswire
Oct-01-15 08:36AM  VERSARTIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
08:30AM  Versartis Presents Confirmatory 18-Month Data From Ongoing Somavaratan Extension Study at Late-Breaker Session at ESPE Annual Meeting GlobeNewswire
Sep-18-15 08:46AM  VERSARTIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits +19.67%
08:00AM  Versartis Announces Confirmatory 18-Month Data From Ongoing Extension Study of Somavaratan in GHD Children GlobeNewswire
Sep-15-15 09:16AM  VERSARTIS, INC. Files SEC form 8-K, Other Events -18.42%
Sep-10-15 08:35AM  Versartis Appoints Lars Ekman, MD, PhD, as Global Development Advisor GlobeNewswire
08:30AM  Versartis Initiates Phase 2 Trial (VITAL) of Monthly Somavaratan in Adults With Growth Hormone Deficiency GlobeNewswire
Sep-08-15 08:30AM  Versartis to Present at Upcoming Investor Conferences GlobeNewswire +8.52%
08:30AM  Versartis Announces Agenda and Event Details for Investor Symposium Featuring Global Opinion Leaders in Pediatric Human Growth Hormone Deficiency (GHD) GlobeNewswire
Aug-11-15 08:30AM  Versartis to Host Investor Symposium Featuring Global Opinion Leaders in Pediatric Human Growth Hormone Deficiency GlobeNewswire -5.36%
Aug-06-15 08:45AM  R. Scott Greer Joins Inogen Board of Directors GlobeNewswire
Aug-05-15 04:35PM  VERSARTIS, INC. Files SEC form 10-Q, Quarterly Report
Aug-04-15 04:22PM  VERSARTIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:15PM  Versartis to Present at the Canaccord Genuity 35th Annual Growth Conference GlobeNewswire
08:39AM  Versartis reports 2Q loss
08:35AM  Versartis Abstract Accepted for Late-Breaker Presentation at the 54th Annual Meeting of the European Society for Paediatric Endocrinology GlobeNewswire
08:30AM  Versartis Reports Second Quarter 2015 Financial Results GlobeNewswire
Jul-08-15 09:05AM  Biotech Stock Roundup: Vertex CF Drug Approved, Biogen Strikes Deal for Gene Therapy - Analyst Blog
Jul-07-15 03:50PM  Versartis (VSAR) Up on Partial Hold Lift on Lead Candidate - Analyst Blog
10:10AM  Company News for July 07, 2015 - Corporate Summary
10:00AM  Story Stocks from Briefing.com Briefing.com
09:32AM  Versartis (VSAR) Catches Eye: Stock Moves 29.4% Higher - Tale of the Tape
Versartis, Inc. operates as an endocrine-focused biopharmaceutical company in the United States. The company is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase 3 clinical trials for the treatment of growth hormone deficiency. It develops drug candidates that it has licensed from Amunix Operating, Inc. The company was founded in 2008 and is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Westberg PaulSr. VP, Corporate DevelopmentJan 11Option Exercise1.617,93112,76952,531Jan 11 09:21 PM
Westberg PaulSr. VP, Corporate DevelopmentJan 11Sale15.247,931120,86844,600Jan 11 09:21 PM
Westberg PaulSr. VP, Corporate DevelopmentJan 10Option Exercise1.4011,21315,64655,813Jan 11 09:21 PM
Westberg PaulSr. VP, Corporate DevelopmentJan 10Sale15.6611,213175,59644,600Jan 11 09:21 PM
Westberg PaulSr. VP, Corporate DevelopmentJan 09Option Exercise1.3613,35618,16557,956Jan 11 09:21 PM
Westberg PaulSr. VP, Corporate DevelopmentJan 09Sale15.9313,356212,76144,600Jan 11 09:21 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 30Buy14.6694,7501,388,8464,013,411Jan 04 02:26 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 29Buy14.3747,375680,5893,918,661Dec 30 08:46 AM
Westberg PaulSr. VP, Corporate DevelopmentDec 27Sale15.853615,72244,600Dec 29 06:19 PM
Brumm Joshua TChief Financial OfficerDec 27Sale15.8599015,69264,824Dec 29 06:15 PM
Westberg PaulSr. VP, Corporate DevelopmentDec 16Option Exercise1.275,0006,32549,961Dec 19 07:37 PM
Westberg PaulSr. VP, Corporate DevelopmentDec 16Sale15.005,00075,00044,961Dec 19 07:37 PM
JENNINGS EDMON RDirectorDec 08Sale12.961,50019,4337,700Dec 08 09:10 PM
Brumm Joshua TChief Financial OfficerDec 07Sale13.253,02140,02865,814Dec 08 05:18 PM
AKKARAJU SRINIVASDirectorOct 03Buy12.25571,4297,000,005571,429Oct 04 12:41 PM
Varian JohnDirectorAug 25Sale12.971,60020,7557,600Aug 26 05:12 PM
Shepard JayPresident and CEOAug 22Sale12.885,44270,093155,358Aug 24 06:22 PM
Brumm Joshua TChief Financial OfficerJun 15Sale10.631,44815,39258,835Jun 17 04:06 PM
Westberg PaulSr. VP, Business DevelopmentJun 15Sale10.637257,70734,961Jun 17 04:05 PM
Brumm Joshua TChief Financial OfficerMay 20Sale7.871,2659,95660,283May 20 07:18 PM